Clinical trial registrations statistics 2026

Clinical trial registrations

The best-covered measure of clinical trial registrations. Every point opens its record; the values are one click away under the chart.

Fig 1 · C21 · Clinical trial registrations Irregular

Clinical trial registrations

Asia-Pacific, 2024 to 2025

2 observations · 2024 to 2025

View the underlying data

Clinical trial registrations
Period	Type	Value
2024	Actual	27,172
2025	Actual	31,097

Source: WHO · CC BY 4.0 · statorigin.org

Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable.

<iframe src="https://statorigin.org/embed/pharmaceuticals--clinical-trial-registrations--trend" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Clinical trial registrations" loading="lazy"></iframe>
<p><a href="https://statorigin.org/statistics/clinical-trial-registrations">Clinical trial registrations</a>, data from StatOrigin, CC BY 4.0</p>

Preview embed

Fig 2 · C21 · Latest by region

Clinical trial registrations by region

Latest value per region, 2025

2 entries

View the underlying data

Clinical trial registrations by region
Category	Source	Type	Value
Asia-Pacific	WHO	Actual	31,097
Africa	WHO	Actual	822

Source: WHO · CC BY 4.0 · statorigin.org

Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable.

<iframe src="https://statorigin.org/embed/pharmaceuticals--clinical-trial-registrations--by-region" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Clinical trial registrations by region" loading="lazy"></iframe>
<p><a href="https://statorigin.org/statistics/clinical-trial-registrations">Clinical trial registrations by region</a>, data from StatOrigin, CC BY 4.0</p>

Preview embed

Every measure of clinical trial registrations

42 measures: the same subject cut by product, segment, basis or form. Each has its own page with every record.

Measure	Latest	Where and when	Records
Clinical trial registrations	31,097	Asia-Pacific, 2025	3
New drug clinical trials	2,997	China, 2025	2
Active Alzheimer's disease drug trials	280	Global, as of 27 Sep 2026	1
Active antibody-drug conjugate trials	1,488	Global, as of 27 Sep 2026	1
Active autoimmune cell therapy and T-cell engager trials	279	Global, as of 27 Sep 2026	1
Active cardiometabolic RNA and next-generation lipid drug trials	90	Global, as of 27 Sep 2026	1
Active gene editing trials	131	Global, as of 27 Sep 2026	1
Active GLP-1, incretin multi-agonist and amylin trials	600	Global, as of 27 Sep 2026	1
Active inflammatory bowel disease drug trials	372	Global, as of 27 Sep 2026	1
Active KRAS and RAS inhibitor trials	217	Global, as of 27 Sep 2026	1
Active oncology bispecific antibody trials	1,109	Global, as of 27 Sep 2026	1
Active radioligand therapy trials	323	Global, as of 27 Sep 2026	1
Bioequivalence trials	2,218	China, 2025	1
Bioequivalence trials share	42.5%	China, 2025	1
Class 1 innovative drug clinical trials	2,171	China, 2025	1
Class 1 innovative drug clinical trials growth rate	4.1%	China, 2025	1
Class 1 innovative drug clinical trials share	72.4%	China, 2025	1
Clinical trial registrations growth rate	6.4%	China, 2025	1
International multi-center clinical trials	410	China, 2025	1
New drug clinical trials growth rate	18%	China, 2025	1
New drug clinical trials share	57.5%	China, 2025	1
Phase 3 Alzheimer's disease drug trials	332	Global, as of 27 Sep 2026	1
Phase 3 antibody-drug conjugate trials	355	Global, as of 27 Sep 2026	1
Phase 3 autoimmune cell therapy and T-cell engager trials	8	Global, as of 27 Sep 2026	1
Phase 3 cardiometabolic RNA and next-generation lipid drug trials	103	Global, as of 27 Sep 2026	1
Phase 3 gene editing trials	11	Global, as of 27 Sep 2026	1
Phase 3 GLP-1, incretin multi-agonist and amylin trials	535	Global, as of 27 Sep 2026	1
Phase 3 inflammatory bowel disease drug trials	449	Global, as of 27 Sep 2026	1
Phase 3 KRAS and RAS inhibitor trials	36	Global, as of 27 Sep 2026	1
Phase 3 oncology bispecific antibody trials	160	Global, as of 27 Sep 2026	1
Phase 3 radioligand therapy trials	51	Global, as of 27 Sep 2026	1
Registered interventional Alzheimer's disease drug trials	1,646	Global, as of 27 Sep 2026	1
Registered interventional antibody-drug conjugate trials	2,351	Global, as of 27 Sep 2026	1
Registered interventional autoimmune cell therapy and T-cell engager trials	336	Global, as of 27 Sep 2026	1
Registered interventional cardiometabolic RNA and next-generation lipid drug trials	237	Global, as of 27 Sep 2026	1
Registered interventional gene editing trials	262	Global, as of 27 Sep 2026	1
Registered interventional GLP-1, incretin multi-agonist and amylin trials	1,963	Global, as of 27 Sep 2026	1
Registered interventional inflammatory bowel disease drug trials	1,698	Global, as of 27 Sep 2026	1
Registered interventional KRAS and RAS inhibitor trials	322	Global, as of 27 Sep 2026	1
Registered interventional oncology bispecific antibody trials	1,525	Global, as of 27 Sep 2026	1
Registered interventional radioligand therapy trials	577	Global, as of 27 Sep 2026	1
Retrospectively registered clinical trials	5,326	Asia-Pacific, 2024	1

Clinical trial registrations by country

A page for every country with at least three records:

CN · 11 records 2,218 Clinical trial registrations in China Bioequivalence trials, 2025

Frequently asked questions

What does clinical trial registrations measure?

Total number of clinical trials registered with a clinical trials registry platform.

What is the latest clinical trial registrations?

Asia-Pacific: 31,097 in 2025, +14.4% on 2024.

Which countries does this clinical trial registrations data cover?

1 country, with a page each for China.

Where does the data come from?

From 33 documents published by ClinicalTrials.gov, NHSA, WHO. Every figure links to its record, which quotes the sentence or table row it was read from.

How often is it updated?

Irregularly, as the publishers release new figures.

Sources

33 documents from 3 publishers; the 20 largest are listed. Each links to the publisher's own copy.

Document	Publisher	Published	Data points
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy registered as Phase 3 (including Phase 2/3), any start date, on 2026-09-27	ClinicalTrials.gov	—	1

Cite this page

Published under CC BY 4.0: free to reuse, including commercially, with attribution to StatOrigin and the original publisher. To cite one figure, open its record.

APA MLA Chicago BibTeX

StatOrigin. (2026). Clinical trial registrations statistics [Data set]. Retrieved September 29, 2026, from https://statorigin.org/statistics/clinical-trial-registrations

"Clinical trial registrations statistics." StatOrigin, 2026, https://statorigin.org/statistics/clinical-trial-registrations. Accessed 29 Sep. 2026.

StatOrigin. "Clinical trial registrations statistics." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/statistics/clinical-trial-registrations.

@misc{statorigin_clinical_trial_registrations_2026, title = {Clinical trial registrations statistics}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/statistics/clinical-trial-registrations}, note = {Data set. Accessed 2026-09-29} }

More pharmaceuticals statistics

All statistics topics →